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asthma patients that reported occurrences of at least one asthma
attack in twelve months. Multiple logistic regression was used to
determine what factors are associated with the risk of absent
controller drug therapy despite the frequent use of quick relief
drugs, i.e., zero use of controllers in 12 months despite the use of
3 or more quick relief canisters in three months. RESULTS: A
total of 1164 patients reported at least one asthma attack in past
12 months. Among these patients, 434 (37%) reported no use of
controller drugs despite the frequent use of quick relief canisters.
The patients that did not have peak ﬂow meter at home were
more likely to report no use of controller drugs despite the
frequent use of quick relief drugs (OR = 1.93; 95% CI:1.92,
1.93). Health insurance (OR = 1.44; 95% CI: 1.43, 1.45) and
prescription drug beneﬁts (OR = 1.21; 95% CI: 1.21, 1.21) also
increased the risk of absent controller drug therapy. CONCLU-
SION: Having peak ﬂow meter increased the likelihood of con-
troller drug use indicating the usefulness of peak ﬂow meter in
asthma treatment and management. Health insurance and pre-
scription drug beneﬁt improved the likelihood of using controller
drugs because of improved access. In order to improve the con-
troller drug utilization amongst asthma patients, attention
should be focused on patients lacking health insurance, prescrip-
tion drug beneﬁts and peak ﬂow meters.
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OBJECTIVE: Rational treatment of bronchial asthma is a
serious problem in developing countries mainly because of access
to medicines. This paper reports the availability and price of two
inhalers in different states of India. METHODS: The data col-
lected for essential medicines at ﬁve sites utilizing a standardized
methodology on medicine prices and availability was used to
collate data for secondary analysis. The surveys were conducted
in public (20–60) and private (20–60) facilities. Anti-asthma
medicines, beclomethasone (50mg/dose) and salbutamol (0.1 mg/
dose) inhalers represented both as innovator brand (IB) and
generic equivalent, were included in the analysis. Medicine prices
were expressed as median price ratio (MPR) to an international
reference price. The surveys were conducted in four states,
Haryana, Karnataka, Maharashtra, Rajasthan and Chennai,
capital TamilNadu, state. Surveys were conducted from
October–December 2004 except Rajasthan survey (April-June
2003). RESULTS: Public sector: Availability—Generic version of
both the inhalers was found only in the Rajasthan state. Avail-
ability of beclomethasone inhaler was 25% and 30% for salb-
utamol. Procurement price –Beclomethasone inhaler was 0.74
and salbutamol inhaler was 0.56 times the international refer-
ence price. Private sector: Availability—Beclomethasone inhaler
was available as innovator brand (55%) and generic version
(90%) in Chennai. In other states only generic version was
available, in the range of 10% to 65%. Salbutamol inhaler
was available in all states and in both the versions, availability
ranging between 20%–95% as innovator brand and 83 -100%
as generic equivalent. Price—MPR for generic beclomethasone
was in the range of 0.87–1.49 at all sites, IB was available in
Chennai and the MPR was 1.08. MPRs for IB and generic
salbutamol range between 0.86–1.12 and 0.82–0.96 respec-
tively. CONCLUSION: Policy interventions are required to
improve access of affordable essential asthma medicines. Asthma
needs to be recognized as a health priority chronic disease in
India.
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OBJECTIVE: To gather information from managed care orga-
nization (MCO) decision makers and employers about asthma
burden, evidentiary requirements, and product attributes that
may inﬂuence formulary decision making for an emerging once-
daily ICS asthma therapy. METHODS: Telephone interviews
were conducted among 10 MCO decision makers and 8
employers representing more than 51 million covered lives.
Research focused on asthma burden, disease management strat-
egies, and formulary decision making. Mean ratings on a scale
from 1 (no effect; not at all important) to 10 (very large effect;
very important). RESULTS: Both MCOs and employers recog-
nized the prevalence of asthma and challenges associated with
management, including patient compliance with ICS. MCOs
reported the economic impact of asthma was most notable in
terms of hospitalizations (7.3), emergency department visits
(7.2), and pharmaceutical costs (7.0). Employers identiﬁed
burden of illness with employee absenteeism (6.0), presenteeism
(5.3), workplace productivity (5.4), and employer health care
costs stemming from both employee asthma and dependent
children with asthma (5.3). ICS product efﬁcacy, safety, com-
pliance, and cost-effectiveness/value were the most important
product attributes driving formulary decision making among
MCOs. Both MCOs and employers had a favorable overall
opinion of the product (6.9 and 6.8, respectively) and felt that
compliance (8.4 and 8.9, respectively) would have a consider-
able impact on decision making. Majority of MCOs (7 of 10)
reported once-daily dosing to be the most important product
attribute (6.9). MCO interviewees emphasized that the product
will need to be priced competitively to secure favorable posi-
tioning in a crowded ICS market. Post-launch evidentiary
requirements may include the need for “real world” head-to-
head comparative effectiveness studies. CONCLUSION: Efﬁ-
cacy, safety, compliance, and cost are primary factors driving
formulary decision making when evaluating emerging ICS
asthma therapies in a crowded market. MCO and employer
organizations have similar priorities with respect to asthma
management and formulary decision making.
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OBJECTIVE: Recent estimates of cost of asthma among chil-
dren in the USA are not available. The objective of this study
was to estimate the incremental direct medical expenditures of
treating asthma among children in the USA. METHODS:
Retrospective analysis was conducted using the 2004 Medical
Expenditure Panel Survey (MEPS) data. Asthmatic children
(age < 18 years; n = 968) were identiﬁed as those with Interna-
tional Classiﬁcation of Diseases (ICD)-9 diagnosis codes for
asthma or those that had a self-report of having asthma in
2004. Separate regression models were developed for total
expenditures and expenditures for various categories of resource
use adjusting for age, gender, race, ethnicity, education, geo-
graphic region, insurance status and number of medications
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used (proxy for comorbidity). Given the skewed distribution of
expenditure variables, multiple model speciﬁcations including
ordinary least squares regression, generalized linear model
(GLM) with Poisson, gamma and negative binomial variance
functions were evaluated. RESULTS: The prevalence of current
asthma among children in 2004 was estimated at 9.09%, i.e.,
6.7 million persons (95% CI: 8.27% to 9.99%) in the U.S. A
majority of children with asthma were male (61.6%), white
(68.1%), and insured (95.2%) with mean age of 8.9  0.25
years and education of 2.4  0.17 years. Children with asthma
had 69% higher total expenditures than non-asthmatics after
controlling for covariates (RR: 1.69; p < 0.0001). The annual
adjusted mean incremental total expenditure associated with
asthma was $661.7 (SE: $159.3; p < 0.0001) per person. Medi-
cations accounted for the largest proportion of the total expen-
ditures estimated at $197.9 (SE: $28.8; p < 0.0001), followed
by physician ofﬁce visits at $162.3 (SE: $57.7; p = 0.005) and
inpatient visits at $105.0 (SE: $75.9; p = 0.0167). CONCLU-
SION: Given the prevalence of asthma in children and its
associated incremental expenditures, the annual direct medical
expenditure for treating asthma in children is estimated at
approximately $4.4 billion in 2005 USD.
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OBJECTIVE: Cigarette smoking is one of the leading avoidable
causes of death in the world. However, in many countries, such
as Brazil, medications used during pharmacological treatments
are not supported by private or public health systems. The
purpose of this study is to analyze and to compare the ﬁnancial
impact of the costs related to adult smokers beneﬁciaries of a
health plan and deﬁne the best strategies to stimulate smoking
cessation programs. METHODS: We analyzed smoking habits,
based on an epidemiologic investigation of 46,407 beneﬁciaries
of a private health plan in Brazil. Expenses with hospitalization
and use of medical services during a period of 12 months, of
beneﬁciaries who report a daily smoking habit were compared
with those of non-smokers. Simulated analysis were performed
with the estimate costs of treatments with anti nicotin drugs a
potential decrease of the costs of the heath plan was estimated.
RESULTS: Among the beneﬁciaries, 29.0% (n = 10,270) were
smokers and 61.8% of those were male. The majority (86.7%) of
the smokers informed to consume 20 cigarettes per day; 9.5%
consumed 20 to 40 cigarettes per day and the rest of the group
(3.8%) consumed more than this amount. 43.3% smoked for less
than 10 years; 25.0% from 10 to 20 years and 31.6% for more
than 20 years. The prevalence of chronic diseases was higher
among the smokers, compared to non-smokers, as well as
average per capita cost expenditures (29% more than the non-
smokers). CONCLUSION: Starting from reported efﬁciency of
the nicotine replacement therapies added to psychological
support, applied to the group of smokers of the health plan and
comparing the costs of this strategy with the effective costs of
those beneﬁciaries, evidences demonstrate the importance of
considering ﬁnancial support systems to smoking cessation
interventions, by the health plan.
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OBJECTIVES: Asthma treatment guidelines and recent cost-
effectiveness models have shifted away from lung function out-
comes and moved toward emphasizing control. We developed
and validated a ﬂexible and transparent adult asthma policy
model that represents disease progression though levels of
asthma control and projects lifetime mortality, morbidity, and
costs. METHODS: We estimated uncertainty and point estimates
of model inputs for non-death transition state probabilities and
health state speciﬁc utilities and health care resource utilization
based on a rigorous analyses of a 3-year, multicenter, observa-
tional study of 4756 patients with difﬁcult-to-treat or severe
asthma receiving standard-of-care. We used statistical regression
models to test and account for population heterogeneity. We
validated the model following the ISPOR Task Force recommen-
dations. Three hypothetical scenarios were compared to
standard-of-care that resulted in different target product proﬁle
and pricing bands: A) a 30% relative reduction in exacerbation
rates with a $2000 per annum treatment cost; B) A plus a
threefold increased risk of asthma related death for the sub-
optimally controlled; C) B plus an absolute improvement in
utility by 0.02 for each health state. RESULTS: Simulation
cohorts, stratiﬁed by age and severity, transitioned through three
mutually exclusive levels of control until reaching death. Nine
health states were modeled because one cycle of control history
was predictive of present cost and utility. Compared to standard-
of-care, the three hypothetical scenarios resulted in societal
perspective incremental cost-effectiveness ratios of $284,000 per
QALY gained (95% interval: $193,000, $463,000), $263,000/
QALY (95% interval: $179,000, $422,000), and $62,000/QALY
(95% interval: $52,000, $72,000) respectively. CONCLU-
SIONS: This policy model adds to past asthma models because
its structure and inputs were based on current clinical guidelines
and a large long-term patient-level registry. This versatile model
can forecast: lifelong burden of disease, value of current and
emerging interventions, and parameters that yield the highest
return from further study.
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OBJECTIVE: This paper contributes to the debate on how
process affects reliability of scientiﬁc evidence in health care. It
discusses the use of different types of study designs in medicine
and biology versus social sciences to raise scientiﬁc international
evidence. METHODS: A comparison of study designs used in
clinical research (RCT and bridges studies (e.g. Hsiao CF et als,
2007)) and in social sciences. Examples from clinical sciences are
on environmental medicine and bridging studies. Examples from
social sciences are presented on two characteristics of six Euro-
pean hypertensive patient surveys on cost of medicines (ENDEP-
Lux, 2000): exemption criteria and classiﬁcation of medicines for
reimbursement. RESULTS: The comparison of case studies
shows similar problems for both clinical and ﬁnancing study
designs: imbalance of sample sizes between new and original sites
for clinical bridges studies, and between national sampled
patients with different access to health beneﬁts for ﬁnancing
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